Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ961MR)

This product GTTS-WQ961MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ961MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4368MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ11270MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ4861MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ3959MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11321MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ12797MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ6317MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ3775MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW